메인 페이지

An innovative challenger

in the field of biotherapeutics.

Our mission
Leading the Future of Healthcare
through R&D Innovation and a Global Value Chain
ATGC currently has two products nearing commercialization through its own research and development capabilities and is planning to expand indications and therapeutic areas.

ATGC'sLab

ATGC currently has two products nearing commercialization through its own research and development capabilities and is planning to expand indications and therapeutic areas.

Our

Pipeline

Botulinum

toxin

type

A complex

(900KDa)

and

non-toxin

botulinum

pure

toxin

type A

(150KDa)

as the main

ingredients

for the

treatment

of frown lines,

a biosimilar

product

with our

process

development

technology.

A liquid

combination

of botulinum

toxin

and

hyaluronic

acid,

a biobetter

aimed at

chondroprotection

and pain

relief for

osteoarthritis.

Recombinant

protein

fusing

a GLP-1

analog

with a

platform

hybrid

IgG,

a novel

therapeutic

with

increased

long-acting

activity

and

efficacy

of GLP-1

for the

treatment

of type 2

diabetes.

Botulinum Toxin
Osteoarthritis
Type 2 Diabetes mellitus

Our Strategy

ATGC has adopted an open innovation strategy that
promotes business through strategic partnerships
based on its core competency of R&D technology.

  • We have adopted an open innovation strategy by partnering with production experts to efficiently spread and distribute medicines resulting from R&D activities.

  • We work with trusted partners to develop and distribute medicines. We work together to plan and execute the marketing and sales of medicines.

Work with us

Making scalable biomaterials a reality for your global supply chains

Get in touch